Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.88 [0.73, 1.06] | | < 1 | | 0% | 1 study (1/-) | 91.6 % | NA | not evaluable | | crucial | - |
progression or deaths (PFS) | 0.71 [0.60, 0.85] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
DOR | 2.14 [1.13, 4.04] | | < 1 | | 0% | 1 study (1/-) | 1.0 % | NA | not evaluable | | non important | - |
objective responses (ORR) | 1.42 [1.05, 1.92] | | > 1 | | 0% | 1 study (1/-) | 98.9 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
AE (any grade) | 5.12 [1.11, 23.56] | | < 1 | | 0% | 1 study (1/-) | 1.8 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 1.37 [0.98, 1.90] | | < 1 | | 0% | 1 study (1/-) | 3.3 % | NA | not evaluable | | non important | - |
AE leading to death (grade 5) | 2.59 [1.36, 4.92] | | < 1 | | 0% | 1 study (1/-) | 0.2 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (any grade) | 2.09 [1.45, 3.02] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
SAE (any grade) | 2.28 [1.66, 3.14] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
STRAE (any grade) | 2.27 [1.46, 3.51] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 1.80 [0.98, 3.28] | | < 1 | | 0% | 1 study (1/-) | 2.8 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 1.57 [1.14, 2.15] | | < 1 | | 0% | 1 study (1/-) | 0.3 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 1.34 [0.30, 6.02] | | < 1 | | 0% | 1 study (1/-) | 35.3 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Adrenal insufficiency TRAE (grade 3-4) | 2.00 [0.07, 59.91] | | < 1 | | 0% | 1 study (1/-) | 34.7 % | NA | not evaluable | | non important | - |
Alopecia TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 1.09 [0.76, 1.58] | | < 1 | | 0% | 1 study (1/-) | 31.9 % | NA | not evaluable | | non important | - |
Arthralgia TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 0.77 [0.28, 2.10] | | < 1 | | 0% | 1 study (1/-) | 69.3 % | NA | not evaluable | | non important | - |
Colitis TRAE (grade 3-4) | 8.08 [0.43, 153.53] | | < 1 | | 0% | 1 study (1/-) | 8.4 % | NA | not evaluable | | non important | - |
Constipation TRAE (grade 3-4) | 0.50 [0.02, 14.93] | | < 1 | | 0% | 1 study (1/-) | 65.3 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 3.41 [0.93, 12.49] | | < 1 | | 0% | 1 study (1/-) | 3.3 % | NA | not evaluable | | non important | - |
Diabetes TRAE (grade 3-4) | 6.05 [0.30, 121.16] | | < 1 | | 0% | 1 study (1/-) | 12.2 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 1.44 [0.54, 3.83] | | < 1 | | 0% | 1 study (1/-) | 23.2 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 1.89 [0.75, 4.80] | | < 1 | | 0% | 1 study (1/-) | 9.0 % | NA | not evaluable | | non important | - |
Febrile neutropenia TRAE (grade 3-4) | 2.66 [1.10, 6.46] | | < 1 | | 0% | 1 study (1/-) | 1.5 % | NA | not evaluable | | non important | - |
Guillain-Barré syndrome TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 1.00 [0.06, 16.05] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 2.00 [0.07, 59.91] | | < 1 | | 0% | 1 study (1/-) | 34.7 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 4.02 [0.18, 89.44] | | < 1 | | 0% | 1 study (1/-) | 19.3 % | NA | not evaluable | | non important | - |
Infusion-related reactions TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
Leucopenia TRAE (grade 3-4) | 1.46 [0.72, 2.93] | | < 1 | | 0% | 1 study (1/-) | 14.7 % | NA | not evaluable | | non important | - |
Myalgia TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
Myositis TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 3.55 [0.73, 17.23] | | < 1 | | 0% | 1 study (1/-) | 5.8 % | NA | not evaluable | | non important | - |
Nephritis TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.93 [0.65, 1.35] | | < 1 | | 0% | 1 study (1/-) | 64.6 % | NA | not evaluable | | non important | - |
Pancreatitis TRAE (grade 3-4) | 2.00 [0.07, 59.91] | | < 1 | | 0% | 1 study (1/-) | 34.7 % | NA | not evaluable | | non important | - |
Peripheral neuropathy TRAE (grade 3-4) | 2.01 [0.37, 11.06] | | < 1 | | 0% | 1 study (1/-) | 21.2 % | NA | not evaluable | | non important | - |
Peripheral sensory neuropathy TRAE (grade 3-4) | 4.04 [0.45, 36.31] | | < 1 | | 0% | 1 study (1/-) | 10.8 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 1.68 [0.40, 7.07] | | < 1 | | 0% | 1 study (1/-) | 24.1 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 2.01 [0.18, 22.23] | | < 1 | | 0% | 1 study (1/-) | 28.7 % | NA | not evaluable | | non important | - |
Severe skin reaction TRAE (grade 3-4) | 1.00 [0.02, 50.55] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 1.16 [0.68, 2.00] | | < 1 | | 0% | 1 study (1/-) | 29.1 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 3.02 [0.31, 29.16] | | < 1 | | 0% | 1 study (1/-) | 17.2 % | NA | not evaluable | | non important | - |